COMMUNIQUÉS West-GlobeNewswire

Sharps Compliance to Attend Gabelli & Company’s 4th Annual Waste & Environmental Services Symposium

14/03/2018 - 13:20

HOUSTON, March 14, 2018 (GLOBE NEWSWIRE) -- Sharps Compliance Corp. (Nasdaq: SMED ) announced today that David P. Tusa, President and Chief Executive Officer, will be presenting at Gabelli & Company’s 4 th Annual [...]

Achaogen to Present at Needham & Company’s 17th Annual Healthcare Conference

14/03/2018 - 13:01

-- Company presentation scheduled for March 27, 2018 -- SOUTH SAN FRANCISCO, Calif., March 14, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO ), a late-stage biopharmaceutical company developing innovative [...]

CASMED Reports 2017 Fourth-Quarter and Full-Year Financial Results

14/03/2018 - 13:00

U.S. FORE-SIGHT sales increased 18% in Q4 on record 80 placements Conference Call Begins Today at 10:00 a.m. Eastern Time BRANFORD, Conn., March 14, 2018 (GLOBE NEWSWIRE) -- CAS Medical Systems, Inc. (NASDAQ: CASM ) ( [...]

MannKind Corporation to Present at Oppenheimer 28th Annual Healthcare Conference

14/03/2018 - 13:00

WESTLAKE VILLAGE, Calif., March 14, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD ) focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as [...]

Melinta Therapeutics to Present at Needham & Company’s 17th Annual Healthcare Conference

14/03/2018 - 13:00

NEW HAVEN, Conn., March 14, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT ), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, [...]

RavenQuest Announces Dr. Simerjeet Kaur Will Lead Scientific Research & Development

14/03/2018 - 13:00

VANCOUVER, British Columbia, March 14, 2018 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) – (CSE:RQB) is pleased to announce it has appointed Dr. Simerjeet Kaur, PhD, to lead Scientific [...]

Proteon Therapeutics Announces Fourth Quarter and Full-Year 2017 Financial Results

14/03/2018 - 13:00

WALTHAM, Mass., March 14, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO ), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular [...]

Spring Bank Announces Presentation of Combined Inarigivir 25 mg and 50 mg 12 and 24 Week ACHIEVE Results Demonstrating Enhanced Anti-Viral Efficacy in HBeAg-Negative Patients

14/03/2018 - 13:00

Data from the combined first two low dose inarigivir cohorts at weeks 12 and 24 with sequential Viread dosing demonstrate significant reductions in HBV DNA, HBV RNA and HBsAg Data to be presented at the APASL 2018 [...]

Clifford Sarkin Appointed to Millennium BlockChain Board of Advisors

14/03/2018 - 13:00

SANTA MONICA, CA, March 14, 2018 (GLOBE NEWSWIRE) -- Millennium BlockChain Inc. (OTC: MBLC ; the “Company”) is pleased to announce that Clifford Sarkin has joined the Company’s board of advisors. Sarkin is a strategic [...]

Inovio’s DNA Immunotherapy Demonstrates Immune Response Results Key in Treating Chronic Hepatitis B Infection

14/03/2018 - 13:00

PLYMOUTH MEETING, Pa., March 14, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO ) today announced that interim Phase 1 results show its DNA immunotherapy designed to treat hepatitis B virus (HBV) [...]

New Data Showing Patient Care Individualized by Daxor’s Precision Blood Volume Analysis Reduces Heart Failure Readmissions by 56% and Mortality by over 80% Presented at the American College of Cardiology 2018 Annual Scientific Session

14/03/2018 - 13:00

(NYSE MKT LLC: DXR) New York, NY, March 14, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR) , an investment company with medical instrumentation and biotechnology operations, announces the presentation of new [...]

FDA Acceptance of IND for Tyme to Begin Phase II Trial in Pancreatic Cancer

14/03/2018 - 13:00

Initial Clinical Sites Expected to Open Over the Coming Weeks NEW YORK, March 14, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME ) (“Tyme” or the “Company”) announced today that the U.S. Food and Drug [...]

K2M Launches Next-Generation YUKON™ OCT Spinal System at AANS/CNS 2018

14/03/2018 - 13:00

LEESBURG, Va., March 14, 2018 (GLOBE NEWSWIRE) -- K2M Group Holdings, Inc. (NASDAQ: KTWO ) (the "Company" or "K2M"), a global leader of complex spine and minimally invasive solutions focused on achieving three- [...]

Abstract on AG200-15 (Twirla®) Accepted for Presentation at the APhA 2018 Annual Meeting & Exposition

14/03/2018 - 12:45

PRINCETON, N.J., March 14, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq: AGRX ), a women's healthcare company today announced that an abstract related to the Phase 3 SECURE study for AG200-15 (Twirla ® ), [...]

Intellia Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results

14/03/2018 - 12:30

Initiated final testing of safety and efficacy in non-human primates (NHP) for our lead program intended to treat patients with transthyretin amyloidosis (ATTR) Completed successful knockout editing in mice of the [...]

Actinium Pharmaceuticals Announces Appointment of Jehan Rowlands, Pharm.D. as Vice-President, Head of Regulatory Affairs

14/03/2018 - 12:30

Dr. Rowlands joins Actinium with almost two decades of experience as a regulatory affairs strategist specialized in the development of first-in-class therapeutics for the treatment of rare and/or serious conditions with [...]

Cellular Biomedicine Group Announces Upcoming Presentation to Release 48-Week Data from Phase I Clinical Trial for AlloJoin™ Off-the-Shelf Allogeneic Stem Cell Therapy for Knee Osteoarthritis

14/03/2018 - 12:30

SHANGHAI, China and CUPERTINO, Calif., March 14, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG ) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of [...]

Voyager Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results

14/03/2018 - 12:02

VY-AADC for advanced Parkinson’s disease on track for start of planned global, pivotal Phase 2-3 program during the middle of this year Two IND filings expected from the ALS, Huntington’s disease and Friedreich’s ataxia [...]

Summit Highlights Scientific Rigour of its PhaseOut DMD Clinical Trial at MDA Clinical Conference

14/03/2018 - 12:01

Summit Therapeutics plc ("Summit" or the "Company") Summit Highlights Scientific Rigour of its PhaseOut DMD Clinical Trial at MDA Clinical Conference Oxford, UK, and Cambridge, MA, US, 14 March 2018 - Summit [...]